JP2024504878A - 弱毒化アフリカ豚熱ウイルス及びワクチンとしてのその使用 - Google Patents

弱毒化アフリカ豚熱ウイルス及びワクチンとしてのその使用 Download PDF

Info

Publication number
JP2024504878A
JP2024504878A JP2023570333A JP2023570333A JP2024504878A JP 2024504878 A JP2024504878 A JP 2024504878A JP 2023570333 A JP2023570333 A JP 2023570333A JP 2023570333 A JP2023570333 A JP 2023570333A JP 2024504878 A JP2024504878 A JP 2024504878A
Authority
JP
Japan
Prior art keywords
virus
asfv
attenuated
asf
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023570333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504878A5 (cg-RX-API-DMAC10.html
Inventor
ル ポティエ,マリーーフレデリック ブロ
ブーリー,オリヴィエ
ヒュテット,エヴリーヌ
ディムナ,ミレイユ ル
シャスタニエ,アメリ
パブーフ,フレデリック
ブランシャール,ヤニック
ルーカス,ピエリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agence National de Securite Sanitaire de l'Alimentation de l'Environnement Et du Travail
Original Assignee
Agence National de Securite Sanitaire de l'Alimentation de l'Environnement Et du Travail
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agence National de Securite Sanitaire de l'Alimentation de l'Environnement Et du Travail filed Critical Agence National de Securite Sanitaire de l'Alimentation de l'Environnement Et du Travail
Publication of JP2024504878A publication Critical patent/JP2024504878A/ja
Publication of JP2024504878A5 publication Critical patent/JP2024504878A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023570333A 2021-02-02 2022-01-31 弱毒化アフリカ豚熱ウイルス及びワクチンとしてのその使用 Pending JP2024504878A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305138.6 2021-02-02
EP21305138.6A EP4036226A1 (en) 2021-02-02 2021-02-02 Attenuated african swine fever virus and its use as a vaccine
PCT/EP2022/052183 WO2022167360A1 (en) 2021-02-02 2022-01-31 Attenuated african swine fever virus and its use as a vaccine

Publications (2)

Publication Number Publication Date
JP2024504878A true JP2024504878A (ja) 2024-02-01
JP2024504878A5 JP2024504878A5 (cg-RX-API-DMAC10.html) 2025-02-06

Family

ID=74661313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570333A Pending JP2024504878A (ja) 2021-02-02 2022-01-31 弱毒化アフリカ豚熱ウイルス及びワクチンとしてのその使用

Country Status (10)

Country Link
US (1) US20240123048A1 (cg-RX-API-DMAC10.html)
EP (2) EP4036226A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024504878A (cg-RX-API-DMAC10.html)
KR (1) KR20230141819A (cg-RX-API-DMAC10.html)
CN (1) CN117295815A (cg-RX-API-DMAC10.html)
BR (1) BR112023015579A2 (cg-RX-API-DMAC10.html)
CA (1) CA3207287A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023008932A (cg-RX-API-DMAC10.html)
PH (1) PH12023552004A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022167360A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115851623A (zh) * 2022-12-27 2023-03-28 中国农业科学院兰州兽医研究所 非洲猪瘟mgf505-2r基因缺失减毒株的构建及作为疫苗的应用
CN118091160B (zh) * 2024-03-09 2025-06-06 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 一种非洲猪瘟病毒抗体的ipma检测方法与试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193685A1 (en) * 2014-06-19 2015-12-23 The Pirbright Institute Attenuated african swine fever virus vaccine
US20160130562A1 (en) * 2014-11-10 2016-05-12 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated African Swine Fever Virus Vaccine Based in the Deletion of MGF Genes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR682468A (fr) 1928-12-13 1930-05-28 Gas Fire Extinguisher Corp Du Extincteur d'incendie
CN110093324B (zh) * 2019-04-26 2020-02-18 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 基因缺失的减毒非洲猪瘟病毒及其作为疫苗的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193685A1 (en) * 2014-06-19 2015-12-23 The Pirbright Institute Attenuated african swine fever virus vaccine
US20160130562A1 (en) * 2014-11-10 2016-05-12 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated African Swine Fever Virus Vaccine Based in the Deletion of MGF Genes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. VIROL., vol. 89, JPN6026000133, 2015, pages 2324 - 2332, ISSN: 0005775442 *

Also Published As

Publication number Publication date
MX2023008932A (es) 2023-10-10
PH12023552004A1 (en) 2023-12-04
US20240123048A1 (en) 2024-04-18
WO2022167360A1 (en) 2022-08-11
BR112023015579A2 (pt) 2023-11-14
CN117295815A (zh) 2023-12-26
EP4036226A1 (en) 2022-08-03
CA3207287A1 (en) 2022-08-11
KR20230141819A (ko) 2023-10-10
EP4288526A1 (en) 2023-12-13

Similar Documents

Publication Publication Date Title
CN110093324A (zh) 基因缺失的减毒非洲猪瘟病毒及其作为疫苗的应用
RU2561595C2 (ru) Вакцина против высокопатогенного репродуктивно-респираторного синдрома свиней (hp prrs)
US9528094B2 (en) Attenuated African swine fever virus vaccine based in the deletion of MGF genes
JP7591043B2 (ja) 遺伝子i177lの欠失に基づく新規なアフリカ豚熱弱毒化生ワクチンの開発
JP2019520827A (ja) 合理的に開発されたアフリカ豚コレラ弱毒化ウイルス株による、ジョージア2007単離株親ウイルスの攻撃に対する防護
US20150165018A1 (en) Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals
CN112852761B (zh) 基因缺失减毒非洲猪瘟病毒株的构建及作为疫苗的应用
CN115717129A (zh) 一种非洲猪瘟病毒基因缺失的重组减毒株及其制备方法与应用
US9463234B2 (en) Attenuated african swine fever virus strain induces protection against challenge with homologous virulent parental virus georgia 2007 isolate
JP2003503039A (ja) 弱毒化したワクチンの操作のための方法および組成物
CN111961654B (zh) 耐热表型稳定遗传、携带负标记的重组口蹄疫病毒无毒株及o/a型口蹄疫二价灭活疫苗
CN114015660A (zh) 缺失十个基因的减毒非洲猪瘟病毒株的构建及其作为疫苗的应用
US20240123048A1 (en) Attenuated african swine fever virus and its use as a vaccine
EP3960850A1 (en) Attenuated african swine fever virus with deleted gene and use of same as vaccine
EP3880804A1 (en) Novel porcine rotavirus
CA3202140A1 (en) Genomic deletion in african swine fever vaccine allowing efficient growth in stable cell lines
CN115851623A (zh) 非洲猪瘟mgf505-2r基因缺失减毒株的构建及作为疫苗的应用
TW202523838A (zh) 新型dev載體
Yan et al. Better immune efficacy triggered by the inactivated gI/gE-deleted pseudorabies virus with the additional insertion of gC gene in mice and weaned pigs
WO2025073910A1 (en) A vaccine for protecting a piglet against african swine fever
EP4680274A1 (en) A vaccine for protecting a pregnant swine against african swine fever
서태영 Clonal Selection of African Swine Fever Virus through Vero Cell Adaptation for Development of a Live Attenuated Vaccine
CN115637260A (zh) 一株表达非洲猪瘟病毒p54基因重组伪狂犬病毒基因工程疫苗及其应用
CN118995642A (zh) 非洲猪瘟与古典猪瘟重组二联活疫苗及其制备方法与应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260623